Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The cancer must have areas that can be measured using standard imaging assessment tools (confirm with trial site).
- People with stomach cancer or cancer of the junction between the stomach and oesophagus that has either spread to other parts of the body (Stage 4) or cannot be removed by surgery (Stage 3), confirmed by laboratory testing of tissue samples.
- People who have already received at least one or two standard treatment options that are available locally, or who were unable to tolerate those standard treatments.
- For people in the dose escalation part of the trial: if a protein called Claudin 18 has previously been tested in the tumour, a certain minimum level of that protein must be present (confirm with trial site for specific thresholds).
- The body's major organs (such as kidneys, liver, and heart) must be functioning well enough to safely participate (confirm with trial site for specific requirements).
- People who agree to have a small tissue sample (biopsy) taken before joining the trial, if it is safe to do so. If a fresh biopsy is not safely possible, a previously collected stored tumour sample may be accepted instead.
Who may not be able to join:
- People whose cancer has spread to the brain or spinal cord, unless it is causing no symptoms, is considered stable, and has not needed steroid medication for at least 14 days before starting the trial treatment.
- People with significant heart disease, lung disease, or liver disease.
- People with an active infection at the time of joining.
- People with a history of inflammatory eye disease.
- People who still have side effects remaining from a previous cancer treatment.
- People who have received another experimental treatment or standard cancer treatment within 28 days before starting the trial treatment, or within a specific timeframe based on how quickly the previous treatment leaves the body — whichever is the shorter period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bolt Clinical Development, Bolt Biotherapeutics
Phone: +1 650 434 8640
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0; Incidence and nature of AEs considered by the Investigator or Sponsor to be clinically relevant, attributable to study treatment, and meeting dose-limiting toxicity (DLT) criteria
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.